Good News: A new collaboration is seeking to upend the current gene therapies approach for sickle cell disease. Today’s therapies are individualized, extremely complex and hugely expensive, STAT reports.
But a new joint effort—from Novartis and the Gates Foundation—aims for a single step treatment, especially in sub-Saharan Africa, home to 80% of those affected by the disease.
Bad News: A gene therapy trial for the disease has been shut down after 2 participants developed a leukemia-like cancer, Science reports.
Researchers are investigating whether the cancers may have been caused by a virus used to deliver the therapeutic gene or if the cancers were linked to chemotherapy they received before the therapy.